COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses

Muhammad Adnan Shereen, Suliman Khan, Abeer Kazmi, Nadia Bashir, Rabeea Siddique, Muhammad Adnan Shereen, Suliman Khan, Abeer Kazmi, Nadia Bashir, Rabeea Siddique

Abstract

The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in Wuhan, China and spread around the world. Genomic analysis revealed that SARS-CoV-2 is phylogenetically related to severe acute respiratory syndrome-like (SARS-like) bat viruses, therefore bats could be the possible primary reservoir. The intermediate source of origin and transfer to humans is not known, however, the rapid human to human transfer has been confirmed widely. There is no clinically approved antiviral drug or vaccine available to be used against COVID-19. However, few broad-spectrum antiviral drugs have been evaluated against COVID-19 in clinical trials, resulted in clinical recovery. In the current review, we summarize and comparatively analyze the emergence and pathogenicity of COVID-19 infection and previous human coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV). We also discuss the approaches for developing effective vaccines and therapeutic combinations to cope with this viral outbreak.

Keywords: COVID-19; Coronaviruses; Origin; Outbreak; Spread.

© 2020 THE AUTHORS. Published by Elsevier BV on behalf of Cairo University.

Figures

Graphical abstract
Graphical abstract
Fig. 1
Fig. 1
Structure of respiratory syndrome causing human coronavirus.
Fig. 2
Fig. 2
The key reservoirs and mode of transmission of coronaviruses (suspected reservoirs of SARS-CoV-2 are red encircled); only α and β coronaviruses have the ability to infect humans, the consumption of infected animal as a source of food is the major cause of animal to human transmission of the virus and due to close contact with an infected person, the virus is further transmitted to healthy persons. Dotted black arrow shows the possibility of viral transfer from bat whereas the solid black arrow represent the confirmed transfer. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 3
Fig. 3
The life cycle of SARS-CoV-2 in host cells; begins its life cycle when S protein binds to the cellular receptor ACE2. After receptor binding, the conformation change in the S protein facilitates viral envelope fusion with the cell membrane through the endosomal pathway. Then SARS-CoV-2 releases RNA into the host cell. Genome RNA is translated into viral replicase polyproteins pp1a and 1ab, which are then cleaved into small products by viral proteinases. The polymerase produces a series of subgenomic mRNAs by discontinuous transcription and finally translated into relevant viral proteins. Viral proteins and genome RNA are subsequently assembled into virions in the ER and Golgi and then transported via vesicles and released out of the cell. ACE2, angiotensin-converting enzyme 2; ER, endoplasmic reticulum; ERGIC, ER–Golgi intermediate compartment.
Fig. 4
Fig. 4
Betacoronaviruses genome organization; The Betacoronavirus for human (SARS-CoV-2, SARS-CoV and MERS-CoV) genome comprises of the 5′-untranslated region (5′-UTR), open reading frame (orf) 1a/b (green box) encoding non-structural proteins (nsp) for replication, structural proteins including spike (blue box), envelop (maroon box), membrane (pink box), and nucleocapsid (cyan box) proteins, accessory proteins (light gray boxes) such as orf 3, 6, 7a, 7b, 8 and 9b in the SARS-CoV-2 genome, and the 3′-untranslated region (3′-UTR). The doted underlined in red are the protein which shows key variation between SARS-CoV-2 and SARS-CoV. The length of nsps and orfs are not drawn in scale. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 5
Fig. 5
Phylogenetic tree of coronaviruses (content in red is the latest addition of newly emerged SARS-CoV-2 and WSFMP Wuhan-Hu-1 is used as a reference in the tree); The phylogenetic tree showing the relationship of Wuhan-Hu-1 (denoted as red) to selected coronavirus is based on nucleotide sequences of the complete genome. The viruses are grouped into four genera (prototype shown): Alphacoronavirus (sky blue), Betacoronavirus (pink), Gammacoronavirus (green) and Deltacoronavirus (light blue). Subgroup clusters are labeled as 1a and 1b for the Alphacoronavirus and 2a, 2b, 2c, and 2d for the Betacoronavirus. This tree is based on the published trees of Coronavirinae , and reconstructed with sequences of the complete RNA- dependent RNA polymerase- coding region of the representative novel coronaviruses (maximum likelihood method using MEGA 7.2 software). severe acute respiratory syndrome coronavirus (SARS- CoV); SARS- related coronavirus (SARSr- CoV); the Middle East respiratory syndrome coronavirus (MERS- CoV); porcine enteric diarrhea virus (PEDV); Wuhan seafood market pneumonia (Wuhan-Hu-1). Bat CoV RaTG13 Showed high sequence identity to SARS-CoV-2 . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

References

    1. Zhong N., Zheng B., Li Y., Poon L., Xie Z., Chan K. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. The Lancet. 2003;362(9393):1353–1358.
    1. Wang N., Shi X., Jiang L., Zhang S., Wang D., Tong P. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013;23(8):986.
    1. Cui J., Li F., Shi Z.-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–192.
    1. Lai C.-C., Shih T.-P., Ko W.-C., Tang H.-J., Hsueh P.-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;105924
    1. Organization WH. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. World Health Organization, 2020.
    1. Peiris J., Guan Y., Yuen K. Severe acute respiratory syndrome. Nat Med. 2004;10(12):S88–S97.
    1. Pyrc K., Berkhout B., Van Der Hoek L. Identification of new human coronaviruses. Expert Review of Anti-infective Therapy. 2007;5(2):245–253.
    1. Rahman A., Sarkar A. Risk factors for fatal middle east respiratory syndrome coronavirus infections in Saudi Arabia: analysis of the WHO Line List, 2013–2018. Am J Public Health. 2019;109(9):1288–1293.
    1. Memish Z.A., Zumla A.I., Al-Hakeem R.F., Al-Rabeeah A.A., Stephens G.M. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med. 2013;368(26):2487–2494.
    1. Wang C., Horby P.W., Hayden F.G., Gao G.F. A novel coronavirus outbreak of global health concern. The Lancet. 2020
    1. Phan L.T., Nguyen T.V., Luong Q.C., Nguyen T.V., Nguyen H.T., Le H.Q. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med. 2020
    1. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Eurosurveillance. 2020;25(4).
    1. Parry J. China coronavirus: cases surge as official admits human to human transmission. British Medical Journal Publishing Group; 2020.
    1. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020
    1. Kan B., Wang M., Jing H., Xu H., Jiang X., Yan M. Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J Virol. 2005;79(18):11892–11900.
    1. Zheng B.J., Guan Y., Wong K.H., Zhou J., Wong K.L., Young B.W.Y. SARS-related virus predating SARS outbreak, Hong Kong. Emerg Infect Dis. 2004;10(2):176.
    1. Shi Z., Hu Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res. 2008;133(1):74–87.
    1. Paden C., Yusof M., Al Hammadi Z., Queen K., Tao Y., Eltahir Y. Zoonotic origin and transmission of Middle East respiratory syndrome coronavirus in the UAE. Zoonoses Public Health. 2018;65(3):322–333.
    1. Annan A., Baldwin H.J., Corman V.M., Klose S.M., Owusu M., Nkrumah E.E. Human betacoronavirus 2c EMC/2012–related viruses in bats, Ghana and Europe. Emerg Infect Dis. 2013;19(3):456.
    1. Huynh J., Li S., Yount B., Smith A., Sturges L., Olsen J.C. Evidence supporting a zoonotic origin of human coronavirus strain NL63. J Virol. 2012;86(23):12816–12825.
    1. Lau S.K., Li K.S., Tsang A.K., Lam C.S., Ahmed S., Chen H. Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus. J Virol. 2013;87(15):8638–8650.
    1. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020
    1. Chan J.F.-W., Yuan S., Kok K.-H., To K.K.-W., Chu H., Yang J. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020
    1. Chan J.F.-W., Kok K.-H., Zhu Z., Chu H., To K.K.-W., Yuan S. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting. Wuhan. Emerging Microbes & Infections. 2020;9(1):221–236.
    1. van Boheemen S., de Graaf M., Lauber C., Bestebroer T.M., Raj V.S., Zaki A.M. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio. 2012;3(6):e00473–e512.
    1. Raj V.S., Mou H., Smits S.L., Dekkers D.H., Müller M.A., Dijkman R. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–254.
    1. Perlman S., Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009;7(6):439–450.
    1. Glowacka I., Bertram S., Müller M.A., Allen P., Soilleux E., Pfefferle S. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011;85(9):4122–4134.
    1. Bertram S., Glowacka I., Müller M.A., Lavender H., Gnirss K., Nehlmeier I. Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol. 2011;85(24):13363–13372.
    1. Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G. A new coronavirus associated with human respiratory disease in China. Nature. 2020;1–5
    1. Zhou P., Yang X., Wang X., Hu B., Zhang L., Zhang W. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Internet]. 2020;Feb:3.
    1. Xu X., Chen P., Wang J., Feng J., Zhou H., Li X. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sciences. 2020;63(3):457–460.
    1. Wan Y., Shang J., Graham R., Baric R.S., Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol. 2020
    1. Wu A., Peng Y., Huang B., Ding X., Wang X., Niu P. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020
    1. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574.
    1. Chen Y., Liu Q., Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020
    1. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases. 2020;91:264–6.
    1. Li B, Si H-R, Zhu Y, Yang X-L, Anderson DE, Shi Z-L, et al. Discovery of Bat Coronaviruses through Surveillance and Probe Capture-Based Next-Generation Sequencing. mSphere. 2020;5(1).
    1. Gralinski L.E., Menachery V.D. Return of the coronavirus: 2019-nCoV. Viruses. 2020;12(2):135.
    1. Xu X., Chen P., Wang J., Feng J., Zhou H., Li X. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;1–4
    1. Corman V.M., Ithete N.L., Richards L.R., Schoeman M.C., Preiser W., Drosten C. Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat. J Virol. 2014;88(19):11297–11303.
    1. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv; 2020.
    1. Gretebeck L.M., Subbarao K. Animal models for SARS and MERS coronaviruses. Cur Opin Virol. 2015;13:123–129.
    1. Cockrell A.S., Peck K.M., Yount B.L., Agnihothram S.S., Scobey T., Curnes N.R. Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection. J Virol. 2014;88(9):5195–5199.
    1. Nagata N., Iwata N., Hasegawa H., Fukushi S., Yokoyama M., Harashima A. Participation of both host and virus factors in induction of severe acute respiratory syndrome (SARS) in F344 rats infected with SARS coronavirus. J Virol. 2007;81(4):1848–1857.
    1. Sheahan T.P., Sims A.C., Leist S.R., Schäfer A., Won J., Brown A.J. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):1–14.
    1. Wang Z., Chen X., Lu Y., Chen F., Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. BioScience Trends. 2020
    1. Richardson P., Griffin I., Tucker C., Smith D., Oechsle O., Phelan A. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet. 2020
    1. Ng C.S., Kasumba D.M., Fujita T., Luo H. Spatio-temporal characterization of the antiviral activity of the XRN1-DCP1/2 aggregation against cytoplasmic RNA viruses to prevent cell death. Cell Death Differ. 2020:1–20.
    1. Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce H. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020
    1. Wang B.X., Fish E.N. Elsevier; 2019. editors. Global virus outbreaks: Interferons as 1st responders. Seminars in immunology.
    1. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;1–3
    1. Agostini M.L., Andres E.L., Sims A.C., Graham R.L., Sheahan T.P., Lu X. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221–e318.
    1. Derebail V.K., Falk R.J. ANCA-associated vasculitis—refining therapy with plasma exchange and glucocorticoids. Mass Medical Soc. 2020
    1. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. bioRxiv; 2020.
    1. Bisht H., Roberts A., Vogel L., Subbarao K., Moss B. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology. 2005;334(2):160–165.
    1. Kam Y.W., Kien F., Roberts A., Cheung Y.C., Lamirande E.W., Vogel L. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro. Vaccine. 2007;25(4):729–740.
    1. Yang Z-y, Kong W-p, Huang Y., Roberts A., Murphy B.R., Subbarao K. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004;428(6982):561–564.
    1. Stadler K., Roberts A., Becker S., Vogel L., Eickmann M., Kolesnikova L. SARS vaccine protective in mice. Emerg Infect Dis. 2005;11(8):1312.
    1. Kapadia S.U., Rose J.K., Lamirande E., Vogel L., Subbarao K., Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology. 2005;340(2):174–182.
    1. Bisht H., Roberts A., Vogel L., Bukreyev A., Collins P.L., Murphy B.R. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci. 2004;101(17):6641–6646.
    1. Buchholz U.J., Bukreyev A., Yang L., Lamirande E.W., Murphy B.R., Subbarao K. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci. 2004;101(26):9804–9809.
    1. Bukreyev A., Lamirande E.W., Buchholz U.J., Vogel L.N., Elkins W.R., St Claire M. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 2004;363(9427):2122–2127.
    1. See R.H., Zakhartchouk A.N., Petric M., Lawrence D.J., Mok C.P., Hogan R.J. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol. 2006;87(3):641–650.
    1. Weingartl H., Czub M., Czub S., Neufeld J., Marszal P., Gren J. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004;78(22):12672–12676.
    1. Spruth M., Kistner O., Savidis-Dacho H., Hitter E., Crowe B., Gerencer M. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine. 2006;24(5):652–661.
    1. Takasuka N., Fujii H., Takahashi Y., Kasai M., Morikawa S., Itamura S. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol. 2004;16(10):1423–1430.
    1. Tang L., Zhu Q., Qin E., Yu M., Ding Z., Shi H. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol. 2004;23(6):391–394.
    1. Qin E., Shi H., Tang L., Wang C., Chang G., Ding Z. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. Vaccine. 2006;24(7):1028–1034.
    1. Zhou J., Wang W., Zhong Q., Hou W., Yang Z., Xiao S.-Y. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine. 2005;23(24):3202–3209.
    1. Qu D., Zheng B., Yao X., Guan Y., Yuan Z.-H., Zhong N.-S. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine. 2005;23(7):924–931.
    1. McKay BLP. Drugmakers rush to develop vaccines against china virus the wall street journal. [cited 2020 28 January]; Available from: <.
    1. Inovio IP. Inovio selected by cepi to develop vaccine against new coronavirus inovio. [cited 2020 29 January]; Available from: <>.
    1. J.-H.Z.W. Lee LZ. Chinese scientists race to develop vaccine as coronavirus death toll jumps: South china morning post. [cited 2020 29 January]; Available from: <>.
    1. Cheung E. China coronavirus: Hong kong researchers have already developed vaccine but need time to test it, expert reveals: South china morning post. [cited 2020 29 January]; Available from: .
    1. Xinhua. China fast-tracks novel coronavirus vaccine development xinhua. [cited 202 29 January]; Available from: .
    1. Geo-Vax. Geovax and bravovax (wuhan, china) to collaborate on development of coronavirus vaccine. [cited 2020 3 March]; Available from: .
    1. Clover B. Clover initiates development of recombinant subunit- trimer vaccine for wuhan coronavirus (2019-ncov). [cited 2020 6 March]; Available from: .
    1. Huang Y. The SARS epidemic and its aftermath in China: a political perspective. Learning from SARS: Preparing for the next disease outbreak; 2004. p. 116–36.
    1. Holmes K.V. SARS coronavirus: a new challenge for prevention and therapy. J Clin Investig. 2003;111(11):1605–1609.
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. The Lancet. 2020
    1. Perlman S. Another decade, another coronavirus. Mass Medical Soc. 2020
    1. Bolles M., Donaldson E., Baric R. SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission. Current Opin Virol. 2011;1(6):624–634.
    1. Vara V. Coronavirus outbreak: The countries affected. 11 MARCH 2020; Available from: .
    1. Shi Y., Yi Y., Li P., Kuang T., Li L., Dong M. Diagnosis of severe acute respiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsid antibodies in an antigen-capturing enzyme-linked immunosorbent assay. J Clin Microbiol. 2003;41(12):5781–5782.
    1. Dong N, Yang X, Ye L, Chen K, Chan EW-C, Yang M, et al. Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. bioRxiv. 2020.

Source: PubMed

3
Abonner